524516 BACPHAR

Bacil Pharma Share Price

₹39.68 -0.8 (-1.98%)

04 Mar, 2025 06:19

SIP TrendupStart SIP in BACPHAR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -4.41%
  • Over 3 Month -17.93%
  • Over 6 Month + 103.28%
  • Over 1 Year + 277.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Bacil Pharma for Steady Growth!

Invest Now

Bacil Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Bacil Pharma Financials

Bacil Pharma Technicals

EMA & SMA

Current Price
₹39.68
-0.8 (-1.98%)
pointer
  • stock-down_img
  • Bearish Moving Average 13
  • stock-up_img
  • Bullish Moving Average 3
  • 20 Day
  • ₹43.01
  • 50 Day
  • ₹44.61
  • 100 Day
  • ₹42.72
  • 200 Day
  • ₹35.95

Resistance and Support

39.95 Pivot Speed
  • R3 41.01
  • R2 40.75
  • R1 40.21
  • S1 39.41
  • S2 39.15
  • S3 38.61

What's your outlook on Bacil Pharma?

You can only vote for once

Bacil Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-21 Quarterly Results
2024-10-23 Quarterly Results
2024-10-15 Others
2024-09-27 Increase in Authorised Capital
2024-08-14 Quarterly Results

Bacil Pharma F&O

Bacil Pharma Shareholding Pattern

No data available.

About Bacil Pharma

  • NSE Symbol
  • BACPHAR
  • BSE Symbol
  • 524516
  • ISIN
  • INE711D01018

Similar Stocks to Bacil Pharma

Bacil Pharma FAQs

Bacil Pharma share price is ₹39 As on 04 March, 2025 | 06:05

The Market Cap of Bacil Pharma is ₹23.4 Cr As on 04 March, 2025 | 06:05

The P/E ratio of Bacil Pharma is 67.1 As on 04 March, 2025 | 06:05

The PB ratio of Bacil Pharma is 40.6 As on 04 March, 2025 | 06:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23